DW Insights & Inquiries
Case reports and retrospective studies have demonstrated dupilumab’s efficacy in treating bullous pemphigoid. Perhaps approval of dupilumab for bullous pemphigoid is on the horizon.
Advances in genetics and molecular biology have identified pathways confirming the usefulness of targeted therapies in those patients with systemic juvenile xanthogranulomas harboring specific mutations.
Read our top ten most popular issues of the year from DermWorld Insights and Inquiries.
On behalf of the editors and staff of DWI&I, I wish you and your loved ones a healthy, safe, and peaceful 2025 and beyond.
IGM should be considered in inflammatory dermatoses of the breast in women of reproductive age. There are an increasing number of reports of IGM accompanied by extramammary manifestations, notably erythema nodosum.
MEK inhibition may be a new therapeutic pathway to treat disorders demonstrating focal acantholytic dyskeratosis, including Darier disease and Grover disease.
To improve the practice of dermatology, while being stimulating, practical, thought-provoking, and enlightening by offering critical perspectives on current dermatologic literature meant to be used in the clinic today and in the future.
Explore Dermatology World Insights and Inquiries clinical topics by practice focus, condition, and medical journal source.
